Table 2.
Clinical characteristics and reported health problem of patients with HIV/AIDS, TASH, Ethiopia, 2019 (n = 511)
| Patient characteristics | Number of participant n (%) |
Reported health problem in EQ-5D health dimensions | ||||
|---|---|---|---|---|---|---|
| Mobility n (%) |
Self-care n (%) | Usual activity n (%) |
Pain/Discomfort n (%) | Anxiety/Depression n (%) |
||
| CD4 (Cells/mm3) | ||||||
| > 500 | 138 (27.0) | 15 (10.9) | 1 (0.7) | 11 (8.0) | 40 (29.0) | 39 (28.3) |
| 350–500 | 129 (25.2) | 22 (17.1) | 12 (9.3) | 24 (18.6) | 65 (50.4) | 72(55.8) |
| 200–350 | 142 (27.8) | 21 (14.8) | 14 (9.9) | 31 (21.8) | 84 (59.2) | 95 (66.9) |
| 100–200 | 80 (15.7) | 22 (27.5) | 10 (12.5) | 26 (32.5) | 59 (73.7) | 60 (75.0) |
| < 100 | 22 (4.3) | 5 (22.7) | 4 (18.2) | 7 (31.8) | 14 (63.6) | 16 (72.7) |
| WHO clinical stages (at diagnosis) | ||||||
| I | 67 (13.3) | 16 (23.9) | 3 (4.5) | 10 (14.9) | 40 (59.7) | 42 (62.7) |
| II | 77 (15.2) | 11 (14.3) | 6 (7.8) | 15 (19.5) | 40 (51.9) | 40 (51.9) |
| III | 190 (37.6) | 28 (14.7) | 16 (8.4) | 32 (16.8) | 83 (43.7) | 95 (50.0) |
| IV | 171 (33.9) | 27 (15.8) | 14 (8.2) | 40 (23.4) | 97 (56.7) | 102 (59.6) |
| Viral load (Copies/mL) | ||||||
| < 50 copies/ml | 440 (86.1) | 70 (15.9) | 33 (7.5) | 81 (18.4) | 217 (49.3) | 236 (53.6) |
| 51–1000 copies/ml | 17 (3.3) | 3 (17.6) | 2 (11.8) | 2 (11.8) | 9 (52.9) | 10 (58.8) |
| > 1000 copies/ml | 54 (10.6) | 12 (22.2) | 6 (11.1) | 16 (29.6) | 36 (66.7) | 36 (66.7) |
| Treatment regimen | ||||||
| AZT/3TC/EFV | 30 (5.9) | 5 (16.7) | 1 (3.3) | 4 (13.3) | 10 (33.30 | 13 (43.3) |
| AZT/3TC/NVP | 28 (5.5) | 4 (14.3) | 1 (3.6) | 3 (10.7) | 14 (50) | 13 (46.4) |
| TDF/3TC/EFV | 297 (58.1) | 49 (16.5) | 22 (7.4) | 51 (17.2) | 146 (49.2) | 161 (54.2) |
| TDF/3TC/NVP | 37 (7.2) | 4 (10.8) | 4 (10.8) | 10 (27.0) | 19 (51.4) | 19 (51.4) |
| ABC + 3TC + EFV | 40 (7.8) | 9 (22.5) | 5 (12.5) | 8 (20.0) | 28 (70.0) | 27 (67.5) |
| TDF + 3TC + ATV/r | 41 (8.0) | 7 (10.8) | 3 (7.3) | 12 (29.3) | 27 (65.9) | 29 (70.7) |
| Others* | 38 (7.4) | 7 (18.4) | 5 (13.2) | 11 (28.9) | 18 (47.4) | 20 (52.6) |
| Number of medicine | ||||||
| 1 | 208 (40.7) | 25 (12) | 12 (5.8) | 25 (12) | 88 (42.3) | 93 (44.7) |
| 2 | 150 (29.4) | 26 (17.3) | 11 (7.3) | 31 (20.7) | 84 (56.0) | 90 (60.0) |
| 3 | 91 (17.8) | 17 (18.7) | 8 (8.8) | 21 (23.1) | 49 (53.8) | 53 (58.2) |
| 4 | 43 (8.4) | 10 (23.3) | 3 (7) | 12 (27.9) | 27 (62.8) | 30 (69.8) |
| > 4 | 19 (3.7) | 7 (36.8) | 7 (36.8) | 10 (52.6) | 14 (73.7) | 16 (84.2) |
| Duration of treatment | ||||||
| < 1 year | 4 (0.8) | – | – | – | 4(100) | 1 (25) |
| 1–5 years | 120 (23.5) | 19 (15.8) | 8 (6.7) | 27 (22.5) | 74 (61.7) | 77 (64.2) |
| > 5 years | 386 (75.7) | 66 (17.1) | 33 (8.5) | 72 (18.7) | 183 (47.4) | 203 (52.6) |
| Adherence | ||||||
| Good | 466 (91.5) | 77 (16.5) | 38 (8.2) | 90 (19.3) | 236 (50.6) | 252 (54.1) |
| Fair | 13 (2.6) | 3 (13.1) | 1 (7.7) | – | 7 (53.8) | 9 (69.2) |
| Poor | 30 (5.9) | 5 (16.7) | 2 (6.7) | 9 (30) | 17 (56.7) | 20 (66.7) |
| History of Rx failure | ||||||
| Yes | 94 (18.4) | 17 (18.1) | 9 (9.6) | 23 (24.5) | 60 (63.8) | 62 (66) |
| No | 417 (81.6) | 68 (16.3) | 32 (7.7) | 76 (18.2) | 202 (48.4) | 220 (52.8) |
| Comorbidities | ||||||
| No | 349 (68.3) | 47 (13.5) | 21 (6) | 53 (15.2) | 156 (44.7) | 175 (50.1) |
| OIs | 41 (8) | 5 (12.2) | 2 (4.9) | 13 (31.7) | 25 (61) | 28 (68.3) |
| Non-OIs | 121 (23.7) | 33 (27.3) | 18 (14.9) | 33 (27.30 | 81 (66.9) | 79 (65.3) |
Rx, treatment; NVP, Nevirapine; ABC, Abacavir; OIs, Opportunistic infections
*Others: ABC + 3TC + NVP, TDF + 3TC + LPV/r and AZT + 3TC + LPV/r